Catalyst Wire Dossier Catalyst Wire Dossier

Triple-targeted CD19/CD20/CD22 CAR-T cell therapy

· Institute of Hematology & Blood Diseases Hospital, China
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Triple-targeted CD19/CD20/CD22 CAR-T cell therapy, covering 2025-06-03 to 2025-06-03. Get the full timeline:

Most recent: Clinical Trial Update: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia [Phase 1]

See pricing